The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization

Subhash Banerjee, Karan Sarode, Ariel Vinas, Avantika Banerjee, Atif Mohammad, Emmanouil S. Brilakis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Eligible patients with symptomatic PAD or with a history of peripheral artery revascularization should be prescribed antiplatelet monotherapy for secondary prevention of both cardiovascular and limb events, using aspirin, clopidogrel, and/or vorapaxar. Given the significant overlap of PAD and coronary artery disease, the evidence presented in this article may have important implications for management of patients with coronary artery disease.

Original languageEnglish (US)
Pages (from-to)525-535
Number of pages11
JournalCurrent Opinion in Cardiology
Volume30
Issue number5
DOIs
StatePublished - Aug 24 2015

Fingerprint

clopidogrel
Peripheral Arterial Disease
Coronary Artery Disease
Lower Extremity
Arteries
Secondary Prevention
Aspirin
Extremities
Therapeutics
vorapaxar

Keywords

  • Antiplatelet therapy
  • Endovascular revascularization
  • Peripheral artery disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. / Banerjee, Subhash; Sarode, Karan; Vinas, Ariel; Banerjee, Avantika; Mohammad, Atif; Brilakis, Emmanouil S.

In: Current Opinion in Cardiology, Vol. 30, No. 5, 24.08.2015, p. 525-535.

Research output: Contribution to journalArticle

@article{d15ac5dd0b7046fdbbee47bc7ad251ed,
title = "The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization",
abstract = "Eligible patients with symptomatic PAD or with a history of peripheral artery revascularization should be prescribed antiplatelet monotherapy for secondary prevention of both cardiovascular and limb events, using aspirin, clopidogrel, and/or vorapaxar. Given the significant overlap of PAD and coronary artery disease, the evidence presented in this article may have important implications for management of patients with coronary artery disease.",
keywords = "Antiplatelet therapy, Endovascular revascularization, Peripheral artery disease",
author = "Subhash Banerjee and Karan Sarode and Ariel Vinas and Avantika Banerjee and Atif Mohammad and Brilakis, {Emmanouil S.}",
year = "2015",
month = "8",
day = "24",
doi = "10.1097/HCO.0000000000000208",
language = "English (US)",
volume = "30",
pages = "525--535",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization

AU - Banerjee, Subhash

AU - Sarode, Karan

AU - Vinas, Ariel

AU - Banerjee, Avantika

AU - Mohammad, Atif

AU - Brilakis, Emmanouil S.

PY - 2015/8/24

Y1 - 2015/8/24

N2 - Eligible patients with symptomatic PAD or with a history of peripheral artery revascularization should be prescribed antiplatelet monotherapy for secondary prevention of both cardiovascular and limb events, using aspirin, clopidogrel, and/or vorapaxar. Given the significant overlap of PAD and coronary artery disease, the evidence presented in this article may have important implications for management of patients with coronary artery disease.

AB - Eligible patients with symptomatic PAD or with a history of peripheral artery revascularization should be prescribed antiplatelet monotherapy for secondary prevention of both cardiovascular and limb events, using aspirin, clopidogrel, and/or vorapaxar. Given the significant overlap of PAD and coronary artery disease, the evidence presented in this article may have important implications for management of patients with coronary artery disease.

KW - Antiplatelet therapy

KW - Endovascular revascularization

KW - Peripheral artery disease

UR - http://www.scopus.com/inward/record.url?scp=84942566937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942566937&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000208

DO - 10.1097/HCO.0000000000000208

M3 - Article

C2 - 26241710

AN - SCOPUS:84942566937

VL - 30

SP - 525

EP - 535

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 5

ER -